Conference LibraryGated
ESO-T01 · CRS profile · vector-infusion-related toxicity distinct from ex vivo CAR-T
ESO-T01 phase 1(9 patients · r/r MM)的 safety profile · 与 ex vivo CAR-T 的关键差异: - CRS 在 vector 注入后几天出现(in vivo CAR-T 自身生成阶段) - per Nature Medicine 2026 (PMID 41882404): CRS in 4/5(3 grade 3)+ 1 grade 1 ICANS - vector-infusion-related toxicity 是 in vivo 平台 unique 表现 · 不直接 可比 ex viv…
- Type
- evidence
- Domain
- oncology
- Grade
- conference
- License
- LIGHT_HOPE_proprietary
- Provenance
- m622_intel_seed_2026-05-16
- evidence_grade
- A
- category
- in_vivo_car_t_safety
- status
- verified
- instance_tag
- sunvax-antibody-2025
- clinical_claim_softening
- "early IIT phase 1 safety data · feasibility / signal only · NOT validated safety / efficacy late-stage model · not intended to guide individual patient treatment choices"
- indication
- relapsed/refractory multiple myeloma
- patient_count
- 5
- trial_id
- IIT in China · per EsoBiotec 2024-12-11 PR
- safety_summary
- CRS in 4/5 patients (3 grade 3) per Nature Medicine 2026 phase 1 report · 1 grade 1 ICANS · vector-infusion-related toxicity distinct from ex vivo CAR-T CRS profile · NOT directly comparable
Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.